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Summary 
Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic 
responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell 
proliferation and immunoglobulin secretion in a major histocompatibility complex-unrestricted 
and contact-dependent manner. We find that such activated  human CD4 + T  cells, but not 
control Ig-treated T cells, may induce normal or leukemic B cells to express B7/BB1 and significantly 
higher levels of CD54 intercellular  adhesion molecule 1 via a process that also requires  direct 
cell-cell contact. To discern what cell surface molecule(s)  may be responsible  for signalling B 
cells to express B7/BB1, we added various monoclonal antibodies (mAbs) specific for T  or B 
cell accessory molecules or control mAbs to cocultures of c~-CD3-activated  T cells and resting 
B cells. We find that only ol-CD40 mAbs can significantly inhibit the increased expression  of 
B7/BB1, suggesting that the ligand for CD40 expressed on activated T ceils may be an important 
inducer of B7/BB1 expression. Subsequent experiments in fact demonstrate that cr  mAbs, 
but not control mAbs, induce changes in B cell phenotype similar to those induced by activated 
T cells when the mAbs are presented on Fc"/RII (CDw32)-expressing L ceils. These phenotypic 
changes have significant effects on B cell function. Whereas chronic lymphocytic leukemia (CLL) 
B cells normally are very poor stimulators in allogeneic mixed lymphocyte reactions (MLRs), 
CLL-B ceils preactivated via CD40 crosslinking are significantly better presenters of aUoantigen, 
affecting up to 30-fold-greater  stimulation of T cell proliferation than that induced by control 
treated or  nontreated CLL-B cells. Similarly,  the MLR  of T  cells stimulated by allogeneic 
nonleukemic B cells can be enhanced significantly  if the stimulator B cells are preactivated via 
CD40 crosslinking. The enhanced MLR generated by such preactivated B ceils may be inhibited 
by blocking B7/BB1-CD28 interaction with CTLA4Ig. These studies demonstrate a novel, CD40- 
dependent pathway for inducing B cell expression  of B7/BB1 and enhancing B cell antigen- 
presenting cell activity that can be initiated via cell-ceU contact with ot-CD3-stimulated CD4 + 
T  cells. 
B  cells may play an important role in antigen presentation 
(1-5).  Cognate interactions between T and B cells may 
result in bidirectional stimulatory signals, allowing properly 
activated B cells both to induce T cell proliferation and to 
elicit  helper activity from T  cells that  recognize antigen 
presented by B cell MHC molecules. It is important that the 
B cell phenotype may influence whether such cognate inter- 
actions result in either T  cell activation or anergy (6). For 
example,  resting B  cells generally are ineffective  stimula- 
tors of allogeneic T cells in the mixed lymphocyte reaction 
(MLR) 1 unless preactivated by oMgM antibodies, PMA or 
LPS (7-9). In addition, soluble monomeric antigen directed 
1 Abbreviations used in this paper: CLL, chronic lymphocytic leukemia; 
MFIK, mean fluorescence  intensity ratio; MLR, mixed lymphocyte reaction; 
Pl, propidium iodide; RPMI-10, penicillin-streptomycin; SM, staining me- 
dia; VCAM-1, vascular cell adhesion molecule 1; VLA-4, very late antigen 4. 
to B cells for presentation in vivo may result in specific T 
cell anergy (10). However,  that same antigen may stimulate 
a vigorous antigen-specific immune response when delivered 
as a divalent molecule that can crosslink B cell surface Ig. 
Recent studies have indicated that the interactions between 
B and T cell surface molecules, such as intercellular  adhesion 
molecule 1 (ICAM-1)  (CD54) and LFA-1 (CD11a/CD18), 
LFA-3  (CD58)  and  CD2,  very  late  antigen  4  (VLA-4) 
(CDw49d) and vascular cell adhesion molecule 1 (VCAM- 
1), and B7/BB1 and CD28, play important roles in B-T cell 
conjugate formation and in patterning the response to B 
cell-presented antigen (11-15). In particular,  B cell expres- 
sion of B7/BB1, induced by slg crosslinking (16, 17), may 
activate antigen-specific T cells to secrete IL-2 and to proliferate 
in response  to B  cell-presented antigen,  thereby possibly 
preventing the induction of antigen-specific T cell anergy (6, 
18-21). 
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pression of these important B cell accessory molecules. Prior 
studies demonstrated that T  cells, activated by TCR cross- 
linking  with  o~-CD3  mAb  or  Con  A  may induce  B  cell 
proliferation, differentiation,  and  Ig  secretion in  an MHC 
and antigen-independent manner that requires direct T-B cell 
contact (22-28). These studies primarily addressed how such 
activated T  cells may induce B cells to differentiate into Ig- 
secreting cells. However, because of the pivotal role that sur- 
face phenotype may play in determining  whether  a B  cell 
can function as a stimulatory APC,  we assayed for changes 
in the levels of accessory molecules expressed by B cells after 
coculture with control Ig-treated or ot-CD3-activated T cells. 
To examine the changes induced by activated T  cells on 
relatively homogeneous  populations  of resting  B  cells,  we 
performed initial studies using chronic lymphocytic leukemia 
(CLL) B cells.  CLbB cells coexpress CD19,  CD20,  CD40, 
CD45,  and class I and II MHC antigens,  and, like a subset 
of normal  B  cells,  are CD5 §  (29-32).  The leukemia  cells 
from most patients express surface IgD and/or lgM and have 
levels of CD54  and CD58  that  are comparable with  those 
of normal resting B cells (33). CLL-B cells are poor stimu- 
lators in autologous or allogeneic MLR (34, 35). Arguably 
consistent with this, CLL-B cells express low levels of CDlla 
and VLA-4 (36, 37), and little to no B7/BB1 (16). Although 
CLL-B cells are similar in many respects to normal resting 
B cells, we performed parallel experiments with normal pe- 
ripheral blood and tonsillar B cells to examine whether any 
noted effects were peculiar to leukemic B  cells. 
Materials and Methods 
Antibodies.  64.1, a murine IgG2a c~-CD3 mAb, was provided 
by Bristol-Myers Squibb  (Seattle,  WA).  G28-5 (a murine IgG1 
c~-CD40 mAb, [38]) was a gift from Dr. Edward Clark (Univer- 
sity of Washington, Seattle, WA). Murine mAbs specific for CDlla 
(IgG1 anti-LFA-1), CD54 (IgG1 anti-ICAM-1),  CD58 (IgG2a anti- 
LFA-3), HLA-DR (IgG2b), or CDw49d (IgG1 anti-VLA-4) were 
purchased from AMAC,  Inc.  (Westbrook,  ME).  PE-conjugated 
cr  (B4, a murine IgG1) was purchased from Coulter Immu- 
nology (Hialeah, FL). MOPC21 (marine IgG1) was purchased from 
Caltag,  Inc.  (South San Francisco,  CA). RPC-5 (murine IgG2a) 
was purchased from Calbiochem Novabiochem Corp. (La Jolla, CA). 
c~-CD14 (done  LeuM3,  a  murine  IgG2b)  and  cr  (done 
Leulla, a murine IgG1)  were purchased from Becton Dickinson 
& Co. (San Jose, CA). ~-B7/BB-1 (clone L307.4, a murine IgG1) 
was purchased from the Advanced  Cellular Biology Division of 
Becton Dickinson & Co. (San Jose, CA) and conjugated to FITC 
as described (39). HB57 (murine IgG1 cr  IgM) and W6/32 
(murine IgG1 ~-HLA class I) producing hybridomas were obtained 
from American Type Culture Collection (Rockville, MD),  and 
mAbs were purified from ascites as described (40). The CTLA4Ig 
human Ig-recombinant molecule (41), was a gift from Dr. Peter 
Linsley (Oncogen Division, Bristol-Myers Squibb). Goat o~-human 
IL-4 was purchased from R & D Systems, Inc. (Minneapolis,  MN). 
Cell Purification.  Human T and B cells were purified from burly 
coats obtained from normal donors at the San Diego Blood Bank 
(San Diego, CA). PBMC were isolated by centrifuging over Histo- 
paque 1077 (Sigma Immunochemicals, St. Louis, MO) and mono- 
cytes depleted by adherence to plastic culture flasks for 2 h in a 
37~  5% COs incubator in RPMI-1640 media plus 10% FCS, 
4 mM t-glutamine, and 100 U/ml penicillin-streptomycin (here- 
after referred to as RPMI-10).  Monocyte-depleted PBL were in- 
cubated with antibodies directed at B cells (c~-CD19), NK cells 
(c~-CD16), and monocytes (c~-CD14), at 1 #g of mAb per 106 es- 
timated target cells, for 30 rain at 4~  washed, and incubated with 
sheep ~-mouse IgG-conjugated magnetic beads (Dynal, Inc., Great 
Neck, NY) at a bead to target cell ratio of 7:1 for 1 h, rocking, 
at 4~  Magnetic depletion of bead-bound cells resulted in >95% 
pure CD3 ~ T  cells,  as determined by FACS  |  analysis (Becton 
Dickinson & Co.). Normal B cells were purified from tonsil samples 
and peripheral blood with magnetic beads as described above, sub- 
stituting c~-CD3 mAb for c~-CD19. CLL PBMC samples  were 
purified only if B cells constituted <95%  of the total cells. In 
normal cell samples, we generally obtained populations consisting 
of 80-95% CD19 § B cells. Cells were used fresh or viably frozen 
in FCS plus  10% DMSO in liquid nitrogen before use. 
64.1 Activated T  Cell Assay.  T-B cocultures were performed 
using a protocol modified from that described by Tohma and Lipsky 
(26). 12-weU  culture plates (Coming Inc., Coming, NY) were coated 
with c~-CD3 mAb (64.1) or control IgG2a mouse myeloma pro- 
tein (RPC-5) at 100 ng/ml in 50 mM Tris buffer, pH 8.5, at room 
temperature for 2-4 h (0.5 ml/well). Wells were washed thoroughly 
with sterile  PBS followed by RPMI-10.  Purified normal T  cells 
were  suspended  at  5  x  106/ml  in  RPMI-10  and  treated with 
mitomycin C (Sigma Immunochemicals) at a concentration of 50 
#g/ml for 1 h at 37~  to prevent proliferation. T cells were then 
washed 4 times with 1KPMI-10, plated onto mAb-coated wells at 
6  x  106/well,  and allowed  to adhere for 1 h  at 37~  CLL or 
normal B cells were added in RPMI-10 at 2  x  106 cells/well. Cells 
were cultured  at  37~  in  5%  CO2,  and  then  harvested  after 
48-72 h for flow cytometric analysis. 
MuhilmrameterFlow Cytometric Analysis.  Cells were washed and 
then suspended  in staining media (SM; consisting of lx  HBSS, 
3% BSA, .01% NAN3, and 1/~g/ml propidium iodide [PI]) with 
saturating amounts of FITC- or PE-conjugated mAbs against var- 
ious cell surface antigens or isotype-specific  control mAbs.  After 
30 min at 4~  cells were washed in PI-deficient SM and analyzed 
on a flow cytometer (FACScan|  Becton Dickinson & Co.). Dead 
cells staining with PI were excluded  from analysis. B cells were 
distinguished from cocultured T cells by electronic gating on cells 
staining with CD19-PE. The expression  of all other cell surface 
markers was determined by staining with FITC-conjugated mAbs, 
as described  above. 
CDW32-L Cell Assay.  We employed a modified version of the 
B cell in vitro culture system described by Banchereau ~t al. (42). 
Briefly, CDw32-expressing murine fibroblast cells (CDw32-L cells) 
obtained from the American Type Culture Collection (Rockville, 
MD), were suspended  at 5  x  106/ml and then treated with 100 
#g/ml mitomycin C in RPMI-10 for 1 h at 37~  These cells then 
were washed four times in PBS plus 50% RPMI-10. In assays for 
FACS  |  analysis of surface phenotype changes,  5  x  105 CDw32-L 
cells in 0.5 ml RPMI-10 per well were plated into a 24-well culture 
plate (Coming Inc.) and allowed to adhere for/>1 h at 37~  B 
cells then were added at 2  x  10  ~ per well in final volume of 1 ml. 
Various mAbs and/or recombinant human IL-4 (rhlL-4; Biosource 
International,  Camarillo, CA) were added at various  concentra- 
tions. Cultures were incubated 48-72 h before harvesting for FACS  | 
analysis. 
MLR.  CLL-B cells were stimulated for 48 h with cr  or 
control mAb plus IL-4 as above, but using 6-well culture plates 
with 1.5  x  106 CDw32-L cells/well and 6  x  106 B cells/well in 
a total volume of 4 ml RPMI-10. B cells were separated from ad- 
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resulting in >99% pure leukemic B cells as assessed  by FACS  |  anal- 
ysis. B cells were treated with mitomycin C as above, washed four 
times in KPMI-10, and then suspended in RPMI plus 10% pooled 
human  AB serum (RPMI-10 hAB; GIBCO BILL; Gaithersburg, 
MD). B cells were plated with various blocking or control mAbs 
in 150 #1 KPMI-10 hAB in triplicate in 96-well round-bottomed 
plates  (Corning  Inc.)  at  105 to 400 cells/well  to give final re- 
sponder T cell to stimulator B cell (R/S) ratios of between 1:1 and 
25:1. After allowing mAbs to bind for 1 h at 37~  responder al- 
logeneic normal T cells, isolated as described above, were added 
at 10S/well in a final total volume of 200/zl, and plates were in- 
cubated at 37 ~ 5% CO2 for 5 d. Proliferative response was mea- 
sured  by pulsing  the cultures  with  1 /xCi/well  [3H]thymidine 
(ICN Biomedicals, Inc., Costa Mesa, CA) 18 h before harvesting 
onto glass fiber filters (PHD Cell Harvester; Cambridge Technology, 
Inc., Watertown,  MA). Filter-bound [3H]thymidine that had been 
incorporated into newly synthesized DNA was measured using a 
scintillation counter (model LS1 801; Beckman Instruments,  Inc., 
Fullerton,  CA). 
Results 
B  Cell  Surface Phenotype Changes Induced by Activated 
Cells.  CLbB cells or normal human B cells were cultured 
alone or with allogeneic, mitomycin C-treated T cells previ- 
ously plated in culture wells coated with either cr  mAb 
(64.1) or control mouse IgG of the same isotype. As described 
(26, 43), a-CD3 mAb-coated plates may induce T lympho- 
cytes to become "activated T  cells" (T, cells),  affecting in- 
creases in T  cell intravascular Ca  2+ ([Ca 2+ ]i), phosphatidyl- 
inositol turnover,  protein tyrosine kinase activity, proliferation, 
and expression of HLA-DR and CD25  (44-48).  The term 
"resting  T  cells" (T~ cells)  is  used to  describe mitomycin 
C-treated T lymphocytes cultured in control Ig-coated wells. 
Flow cytometric analyses  indicated that, whereas <10%  of 
Tr cells expressed CD25 and/or HLA-DR, >50% of the T, 
cells used in these studies expressed these T  cell activation 
antigens (data not shown). B cells cultured either alone or 
in control Ig-coated wells or with Tr or T, cells were ex- 
amined by flow cytometry after 48 h in culture. We find that 
B cells cocultured with T, cells dramatically increase their 
expression of CD54 (ICAM-1) and B7/BB1 (Fig. 1 C). B cells 
cocultured with T, cells also manifest moderate increases  in 
surface expression of CD11a and CD58, compared with B 
cells cultured alone (Fig.  1/t).  On the other hand,  B cells 
cocultured with T, cells displayed minimal changes in their 
expression levels of B7/BB1, CD54, CDlla or CD58 (Fig. 
1 B), as did B cells cultured in o~-CD3  mAb-coated wells 
without  added T  cells  (data not  shown). 
To compare changes in expression levels of these B cell an- 
tigens within and across experiments, we computed the mean 
fluorescence intensity ratio (MFIR) in each staining experi- 
ment for each antigen.  The MFIR for a given antigen is defined 
as the mean fluorescence intensity (MFI) of gated B cells stained 
with an antigen-specific FITC-conjugated mAb divided by 
the MFI of such cells stained with a FITC-conjugated iso- 
type control mAb of irrelevant  specificity.  For example, B 
cells cocultured with Ta cells in the experiment depicted in 
Fig.  1 C  had a MFIR for BV/BB1 of 6.1,  and a MFIR for 
CD54 of 55.7. On the other hand,  B cells cocultured with 
Tr cells (Fig.  1 B) had a B7/BB1 MFIR of 1.0, identical to 
that noted for B cells cultured alone. To compare the MFIRs 
observed in separate experiments, we calculated the ratio of 
the MFIR for a given antigen observed on B cells cocultured 
with  T, or T~ cells  over the MFIR for that  same antigen 
observed on B cells cultured alone. We find that, on average, 
CLbB cells cocultured with T, cells have B7/BB1 MFIRs 
and CD54 MFIRs that are, respectively, 4.8- and 23.5-fold 
greater than that of B cells cultured alone (n  =  7). In con- 
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Figure  1.  Changes in surface  antigen pheno- 
type of B cells cocultured with Tr or T, cells. 
CLL-B cells were  cultured alone in control 
IgG2a-coated  wells (A),  or with allogeneic 
mitomycin C-treated  T  cells in wells coated 
with control  IgG2a  mAb (% cells) (B), or 
with  the a-CD3  mAb 64.1 (Ta cells) (C). 
After 48 h of coculture, B cell accessory mole- 
cule expression  was assessed by FACS  |  analysis. 
Each histogram depicts the logarithmic green 
fluorescence intensity of live-gated CD19 § B 
cells stained with either  a FITC-conjugated 
mAb specific for a cell surface antigen (listed 
below each column) or FITC-conjugated mouse 
isotype control Ig. The histogram that is nearest 
the ordinate in each figure represents  the fluores- 
cence of B cells stained with an isotype con- 
trol Ig. 
927  Ranheim and Kipps trast,  T, cells mediated  only 2.7-  and  2.1-fold  increases in 
CDlla (n  =  3) and CD58 (n  =  4) MFIRs, respectively, over 
those measured in B cells cultured alone. Studies employing 
normal tonsillar  and peripheral blood B  cells revealed very 
similar responses to those obtained with CLL-B cells. Cocul- 
ture of normal B cells with allogeneic T, cells induced 3-10- 
fold increases in B7/BB1 expression and 15-32-fold increases 
in the expression of CD54 as compared with levels observed 
on B cells cultured alone. As with CLL-B cells, coculture with 
T~ cells  was without  effect. 
T,  Cells that  Induce  B  Cell  Expression  B7/BB1  Are 
CD4 +.  To further characterize the T~ cells that may induce 
B cells to express B7/BB1,  isolated normal peripheral blood 
T  cells were separated into CD4 + or CD8 + cell populations 
by magnetic bead depletion  of CD8 + cells or CD4 + cells, 
respectively. CD4 + T~ induced  an 8.3-fold increase in B7/ 
BB1 MFIR on cocultured  CLIMB cells compared with that 
on CLL-B cells cultured  alone (Fig.  2).  In contrast,  CD8 + 
T,  cells  induced  minimal  changes  in  B  cell  expression  of 
B7/BB1,  similar to that induced by CD8 + or CD4 + T~ cells 
(Fig.  2). 
Induction of B7/BB1  Requires Direct T-B  Celt  Contact. 
Previous studies demonstrated that the stimulatory effects of 
o~-CD3-activated T  cells on B cell proliferation and Ig produc- 
tion were dependent  on direct cell-cell contact (25, 26).  To 
examine whether  the  increased  expression  of B7/BB1  was 
mediated by soluble factors or required cell-cell contact, we 
cultured  CLL-B  cells  together  with  T,  or  Tr  cells,  or  in 
chambers separated from the T  cells by membranes that are 
permeable to particles ~<0.4 #m in diameter (Transwell  |  in- 
serts;  Costar Corp.,  Cambridge,  MA).  We find that direct 
contact with T, cells results in a B7/BB1  MFIR of 3.3,  as 
compared to B7/BB1  MFIRs  of 1.4,  1.2,  and  1.5  induced 
by contact with Ta supernatant,  T~ cells or T, supernatant, 
respectively (average of two experiments) (Fig. 3). The subop- 
timal  T~-mediated  induction  of B7/BB1  in  these  experi- 
ments may be due to dilution  of cells into the larger tissue 
culture  wells  necessary  to  accommodate  the  Transwells | 
Maximal  increases  in  CD54  expression  are also dependent 
on direct T,-B cell contact.  Whereas contact  with T, cells 
or supernatants ofT-B coculture increased CD54 MFIRs two- 
to fourfold, direct contact with T, cells induced 20-fold in- 
creases in CD54 MFIR. These results suggest that a cell surface 
molecule(s) is expressed on T cells upon ol-CD3 crosslinking 
which may induce B cells to express B7/BB1  and other sur- 
face molecules  upon  cell-cell contact. 
The Induction of  B7/BBI Is Blocked by cr-CD40 mAbs.  To 
discern what cell surface molecule(s) may be responsible for 
Ta-B cell interaction,  we added each of several mAbs specific 
for T  and/or  B  cell accessory molecules  to cocultures  of B 
and T, cells.  We find that soluble a-CD40  mAb (G28-5), 
but not mAbs specific for HLA class I or II, CD11a (LFA-1), 
or CD58 (LFA-3), can significantly inhibit the induction of 
CLIMB cell surface B7/BB1  expression by T, cells (Fig.  4). 
In five experiments,  we noted  that  cx-CD40 mAb affected 
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Figure  2.  Only CD4 + T, cells are able to induce CLL-B cell expres- 
sion of B7/BBL  Normal peripheral blood T cells were isolated and en- 
riched for either CD4 + or CD8 + cells by magnetic bead depletion of the 
alternate subset. CLL-B cells were cocultured with CD4 + or CD8 + % 
or T, cells for 48 h and assessed for B7/BB1 expression by FACS  # anal- 
ysis. Each histogram depicts the logarithmic green fluorescence intensity 
of live-gated CD19 + B cells stained with either FITC-conjugated oe-B7/ 
BB1 or FITC-conjugated isotype control Ig. The histogram that is nearest 
the ordinate in each figure represents the fluorescence of B cells stained 
with an isotype control Ig. 
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Figure  3.  %-induced increases in B7/BB1 expression require direct 
%-B contact. CLbB cells were cultured in direct contact with Tr (A) 
or T, ceils (B), or in Transwell  |  inserts contacting the supernatants of 
Tr-B cell (C) or T=-B cell (D) cocultures, but separated from direct T cell 
contact by membranes permeable only to particles ~0.4/~m in diameter. 
After 48 h, B cells were assessed for B7/BB1 expression by FACS  |  anal- 
ysis. Each histogram depicts the logarithmic green fluorescence intensity 
of live-gated CD19 + B cells stained with either FITC-conjugated co-B7~ 
BB1 or FITC-conjugated isotype control Ig. The histogram that is nearest 
the ordinate in each figure represents the fluorescence of B cells stained 
with an isotype control Ig. One representative experiment of two. 
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Figure 4.  T,-induced  increases in B7/BB1 
expression are inhibited by t~-CD40 mAbs. 
CLL-B cells were cocuhured with T, or T~ 
cells for 48 h with or without one of several 
mAbs specific  for cell surface  antigens  or con- 
trol Ig (Cont.  IgG), as indicated  in the top fight 
corner of each histogram. Each histogram 
depicts the logarithmic  green fluorescence  in- 
tensity of live-gated CD19  + B cells stained 
with either  FITC-conjugated  mAbs specific  for 
B7/BB1 or FITC-cunjugated  mouse isotype 
control Ig. The histogram that is nearest the 
ordinate in each figure  represents the fluores- 
cence of B ceils stained with an isotype  con- 
trol Ig. 
a 55%  (_+  16%, SD) mean reduction of T~-induced  B cell 
B7/BB1 MFIR compared with that of B cells cocuhured with 
T~ cells and a control mouse IgG1 (p <0.001).  Addition of 
ot-CD40 mAbs also reduced the induced level of CD54 by 
37%  (+  7%, SD) (p  =  .001).  A modest reduction (13  _+ 
6%) in the level of Ta cell-induced B7/BB1 also was noted 
when  saturating amounts of mAbs  specific for CDw49d 
(VLA-4)  were added to the cultures (mean of three experi- 
ments) (Fig. 4). However, this inhibition was not significant 
(p >.05).  In contrast,  saturating amounts of ol-CDlla or 
c~-HLA-DR mAbs, even at concentrations 20 times higher 
than that needed for maximal inhibition by ot-CD40, had 
no effect on T~-cell-induced expression of B7/BB1 or CD54 
(Fig.  4). 
Crosslinking  CD40 Induces Changes  in Surface Phenotype 
Similar  to  Those  Induced by  Ta  Cells.  We  used  Fc~/RII 
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Figure 5.  Expression  of B7/BB1 on B calls cultured with CDw32-L 
cells and mAbs specific  for CD40. Normal or CLL-B  cells enriched from 
tonsil or peripheral blood and mitomycin  C-treated CDw32-L cells were 
cuhured with rhIb4 (10 ng/ml) and control mouse  IgG (A) or o~-CD40 
|  mAb (B) for 48 h and assessed  for B7/BB1 expression  by FACS analysis. 
Each histogram  depicts  the logarithmic  green  fluorescence  intensity  of  live- 
gated CD19  + B cells stained  with either FITC-conjugated  ol-B7/BB1 or 
FITC-conjugated  isotype control Ig. The histogram that is nearest the 
ordinate in each figure represents the fluorescence  of B calls stained  with 
an isotype control Ig. 
(CDw32)-expressing  murine fibroblast cells (CDw32-L cells) 
to present a cell surface array of mAbs specific for B cell sur- 
face roolecules, as described by Banchereau et al. (42). Normal 
tonsillar or peripheral blood B cells, or CLbB cells cultured 
with ot-CD40 mAbs and irradiated CDw32-L cells exhibit 
changes in surface phenotype that closely resemble those in- 
duced by T~ cells, including induced expression  of B7/BB1 
(Fig.  5).  We note that ot-CD40 mAbs appear  to be more 
effective in inducing B7/BB1 and CD54 on CLL-B cells than 
c~-IgM or ot-HLA-DR, two stimuli previously shown to in- 
crease B7/BB1 expression  (16-18).  Crosslinking slgM with 
mAbs presented on CDw32-L cells induces a 1.6-fold or 2.7- 
fold increase in B7/BB1 or CD54 MFIRs, respectively (mean 
of four experiments). 72 h culture with ol-HLA-DR mAbs 
and irradiated CDw32-L cells resulted in similar increases in 
B7/BB1, but no detectable increase in CD54 (data not shown). 
In contrast, 72-h culture with c~-CD40 mABs in the pres- 
ence of Ib4 induced an average 7.2-fold increase in B7/BB1 
MFIR (n  =  15), and an average 54.2-fold increase in CD54 
MFIR (n  =  6) in a dose-responsive  manner (Fig.  6 a, and 
data not shown). Subsequent experiments revealed that normal 
peripheral blood and tonsillar B cells responded similarly to 
CLL-B cells after CD40 crosslinking. Normal B cells from 
three different peripheral blood and three different tonsillar 
samples increased their B7/BB1 MFIR an average of 4.9-fold 
(n  =  6),  and CD54 MFIR, an average of 5.5-fold (n  =  5) 
after 48-h  culture with ot-CD40  mAbs,  CDw32-L  cells, 
and exogenous rhlL-4.  The final CD54 MFIILs achieved in 
cuCD40-stimulated normal B cell cultures were similar to 
those observed  on c~-CD40-stimulated CLL B cells. How- 
ever, since nonstimulated normal B cells expressed higher levels 
of CD54 than nonstimulated CLL B cells, the fold increases 
in CD54 MFIIL achieved with c~-CD40 crosslinking were 
less for normal B cells than for CLL B cells. 
Although not necessary for the ol-CD40-induced pheno- 
typic changes, exogenous rhlb4 augmented the effect of CD40 
crosslinking in  a  dose-responsive  manner  (Fig.  6  b, filled 
squares). IL-4, alone or in combination with control mAbs, 
did not change the level of B7/BB1 expressed by CLL-B cells 
when  cultured  without  T~  cells  or  ot-CD40  mAbs  and 
CDw32-L cells (Fig. 6 b, open square). Furthermore, ot-hlb4 
neutralizing  antibody  at  ~<5  #g/ml  did  not  reduce  the 
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Figure 6.  Dose-response  increase in B7/BB1 MFIR on B cells cultured 
with CDw32-L cells and increasing concentrations  of oe-CD40 mAb or 
II,-4. CLIrB cells and mitomycin C-treated CDw32-L cells were cultured 
with varying concentrations  of oe-CD40 mAb in the presence of a fixed 
concentration  of exogenous rhlL- 4 (10 ng/ml) (a), or with varying con- 
centrations of exogenous rhlI~4 and a fixed concentration of c~-CD40 mAb 
(100 ng/ml) (b). The B7/BB1  MFIRs of such cultured B cells (I)  are 
plotted versus the concentration  of added c~-CD40 mAb (a) or exogenous 
rhlL-4 (b). (["]) The B7/BB1  MFIR of B cells cultured with CDw32-L 
cells and a mouse isotype  control Ig in lieu of the c~-CD40 mAb. 
B7/BB1 MFIR of CLL-B cells cultured with either T~ cells 
or c~-CD40 mAbs and CDw32-L cells, further arguing that 
I1,-4 is not required (data not shown). 
Changes in the expression levels of other surface antigens 
also are observed in o~-CD40-stimulated CLL or normal B 
cells.  The  CD58  MFIR  increased ",~14-fold, whereas the 
CD11a  MFIR  increased only 1-1.8-fold  over that  seen  in 
control-treated cells (data not shown). In addition, the CD23 
MFIR increased up to 80-fold,  similar to the increase ob- 
served for CD54 (data not shown). However, the normally 
high expression levels of class I and II MHC and CD45 on 
CLL-B cells were not affected by CD40 crosslinking (data 
not shown). 
The  kinetics  of oe-CD40  mAb  or  Ta  cell-contact-me- 
diated induction of CD54 or B7/BB1 expression were similar. 
As  with  T~ cell-mediated stimulation,  B7/BB1  increases 
were  noticeable  only  after  18-24  h  of stimulation  with 
ol-CD40 plus IL-4, reaching a maximum sevenfold increase 
in expression level after ,,o72-h culture (Fig. 7). The increase 
in B cell expression of CD54 followed similar kinetics, in- 
creasing nearly twofold at 6 h, fivefold at 12 h, and achieving 
a maximum 70-fold increase after ~70 h of culture. B cells 
cocultured with o~-CD40 and CDw32-L cells for prolonged 
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Figure 7.  Time course of c~-CD40-induced  expression of B7/BBI or 
CD54. CLL-B  cells and CDw32-L cells  were cultured with rhIb4 (10 ng/mI) 
and 100 ng/ml of c~-CD40 mAb (filled symbols) or mouse isotype control 
Ig (open symbols). Parallel  cultures were harvested at various times for FACS  | 
analysis of the live gated CD19 + B cells. The B7/BB1  MFIKs (squares) 
are scaled on the left ordinate  and the CD54 MFIRs (circles) are scaled 
on the right ordinate.  Each value is plotted versus the number of hours 
in culture. 
periods (i>120 h) did not manifest any further increases  in 
expression of B7/BB1 or CD54 (data not shown). Finally, 
cell proliferation was not required, as mitomycin C did not 
affect the ability of B cells to manifest increases in B7/BB1 
or CD54 MFIRs upon coculture with c~-CD40 mAbs and 
CDw32-L cells (data not shown). 
Enhanced Expression of BT/BB1  and other Accessory Mole- 
cules Has Functional Significance.  To determine whether the 
expression of B7/BB1 and other surface molecules induced 
by CD40 crosslinking enhanced the capacity of B cells to 
act as stimulatory APCs, we examined resting and o~-CD40-ac- 
tivated CLb or normal B cells for their ability to present 
alloantigen to normal T cells derived from unrelated donors. 
Control Ig-treated or nontreated CLL-B cells are very poor 
stimulators of allogeneic normal T  cells in the MLR (Fig. 
8 A). Upon cocuhure with cr  plus IL-4 and CDw32-L 
cells, however, CLL-B cells became significantly better pre- 
senters of aUoantigen, affecting a significant increase in T cell 
[3H]thymidine uptake over that observed in T  cells cocul- 
tured with control-treated CLL-B cells (Fig.  8 A,  top two 
bars, p  =  .002).  The ability of normal peripheral blood B 
cells to stimulate allogeneic T  cells also was enhanced sig- 
nificantly by treatment with oe-CD40 presented on CDw32-L 
cells in the presence of exogenous IL-4 (Fig. 8 B, top two bars, 
p  =  .02). 
Various mAbs were added at the beginning of the MLKs 
to determine whether they could inhibit the APC function 
of ovCD40-stimulated allogeneic B cells (Fig. 8, A  and B). 
All blocking reagents were used at concentrations that gave 
maximal inhibition and/or cell surface staining in prelimi- 
nary experiments. The proliferation of T  cells in response 
to o~-CD40-stimulated B cells was not affected significantly 
by addition of control mouse or human IgG of irrelevant 
specificity (data not shown). However, addition of CTLA4Ig, 
a recombinant human Ig capable of blocking B7/BB1/CD28 
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(Fig. 8). Such combinations completely abrogated the allo- 
APC activity of stimulated leukemic or normal B cells. 
We also find that CLbB cells stimulated by contact with 
T~  cells,  but  not  with  T~  cells,  exhibit  enhanced  MLR 
stimulatory capacity,  similar to  what  was  observed  with 
c~-CD40-stimulated CLL-B ceUs. CLbB ceUs were cultured 
alone or with Ta or Tr cells. After 48 h, B ceils were iso- 
lated to >95% purity by magnetic bead depletion of T cells. 
In MLRs, B ceils previously cultured with T~ cells stimu- 
lated  allogeneic T  cells  to  incorporate  significantly more 
[3H]thymidine (9,546  _+  383  cpm) than did B ceils previ- 
ously cuhured alone (2,480  _+  1,579; p  =  0.02) or with Tr 
cells (1,424  _+  598; p <  0.01).  It is unlikely that residual T~ 
cells were responsible  for inducing this increase  in MLR 
stimulatory activity, as the responder T cells in these MLRs 
were autologous to the T~/T~ cells used to stimulate CLL-B 
cells in culture. Also, the MLR response against unseparated 
B-T, cocultured cells was less than that against purified B 
cells alone.  As in MLRs using c~-CD40-stimulated B cells, 
the measured T cell proliferation against T~ cell-stimulated 
B cells was reduced by/>75% in MLR culture wells con- 
taining CTLA4Ig (data not shown). 
Figure  8.  Inhibition  of allogeneic MLR against ct-CD40-treated leu- 
kemic and normal stimulator  B cells. CLL (.4) or normal (B) peripheral 
blood B cells were cultured  with CDw32-L cells, rhlb4 (10 ng/ml), and 
c~-CD40 mAb (100 ng/ml) or mouse isotype  control Ig. After 48 h in 
culture, B cells  were separated  from adherent  CDw32-L  cells, treated  with 
mitomycin  C and then used as stimulator  cells at a 3:1 (responder/stimu- 
lator) ratio in an allogeneic  MLR. T cell proliferation  was measured  by 
the uptake of [3H]thymidine  into DNA, expressed as cpm  x  10-3 (ab- 
sc/ssa). Various  culture  conditions  are listed  on the ordinate.  Control  treated 
CLL (A) and control treated B (B) represent the T cell proliferation  to 
allogeneic  CLL-B  or normal  B stimulator  cells, respectively,  previously  cul- 
tured with CDw32-L cells and control Ig. All other groups represent T 
cell proliferation  affected  by tx-CD40-stimulated  CLL or normal B cells 
in the presence  of control mAb, CTLA4Ig  (B7), tx-CDlla mAb (CDIla), 
c~-CD58 mAb (CD58), CTLA41g and tx-CDlla mAb (B7 +  CDlla), 
CTLA4Ig  and ct-CD58 mAb (B7 + CD58), o~-CDlla  mAb and tx-CD58 
mAb (CDIla + CD58) or CTLA41g,  o~-CDlla  mAb, and ct-CD58 mAb 
(B7 + CDIla  + CD58). There were no significant  differences  between 
responses to c~-CD40-stimulated  B cells alone  or in the presence of con- 
trol human or mouse IgG (data not shown). Results are reported as the 
mean cpm of triplicate wells for each condition (error bars = SD). 
interactions (41), inhibited 82% of the MLR against stimu- 
lated CLL-B cells (Fig.  8 A) and 76% of the MLR against 
stimulated normal B cells (Fig. 8 B) (p <0.01). Addition of 
o~-CDlla inhibited T cell proliferation in response to stimu- 
lated leukemic or normal B cells by 46 or 50%, respectively 
(p  <0.05)  (Fig.  8).  In  contrast,  cr  mAbs  did  not 
significantly inhibit the MLRs, affecting only a 20 or 36% 
reduction in  [3H]thymidine uptake by T  cells  cocultured 
with stimulated leukemic or normal B cells, respectively. The 
combination of ol-CDlla together with ot-CD58, however, 
was strongly inhibitory (p <.01), affecting a >--88% inhibi- 
tion of MLRs (Fig.  8). Even more effective were combina- 
tions of CTLA4Ig and ct-CD11a,  with or without ot-CD58 
Discussion 
We demonstrate that normal human CD4 + T cells which 
are activated by mAb-mediated crosslinking of CD3, but not 
T  cells stimulated with nonspecific  control Ig, may induce 
normal or leukemic B cells to express  substantially higher 
levels of B7/BB1 and CD54,  two accessory molecules that 
are important in T-B conjugate interactions. Such changes 
are not secondary to the outgrowth of BT/BB1- and CD54- 
expressing B ceils, as mitomycin C-treated B ceils that are 
unable to divide also may be induced to express higher levels 
of these surface antigens. Also, the changes in B cell pheno- 
type were not secondary to a direct effect of FcR crosslinking 
due to the solid phase 64.1 mAb, as control Ig of the same 
isotype as 64.1 (IgG2a) failed to stimulate B ceils in T-B co- 
cultures. Furthermore, even the 64.1  mAb did not induce 
surface phenotype changes in B cells unless CD4 § T  cells 
also  were present.  Finally,  to affect substantial changes in 
phenotype, the B cells must be cultured in direct contact with 
TR cells, as evidenced by the failure of soluble factors  from 
the supernatants of Ta cells or Ta-B cocultures to induce B 
cell expression of  B7/BB1. Previous studies demonstrated that 
Ta cell-induced B  cell  proliferation and  Ig  secretion  also 
were contact dependent (22-28). Collectively, these findings 
indicate that a cell surface molecule(s)  may be induced on 
CD4 + T cells that can stimulate resting B cells to undergo 
a variety of phenotypic and/or functional changes. 
Crosslinking CD40  induces B  cell  phenotypic changes 
similar to those caused  by contact with Ta cells. We find 
that soluble mAbs against CD40, but not mAbs against any 
one of a variety of other B cell accessory molecules, can in- 
hibit the T, cell-induced increase in expression  of BT/BB1 
or CD54 on CLL-B cells. On the other hand, c~-CD40 mAbs, 
when presented on a membrane matrix of CDw32-L cells, 
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cules that mimic those induced by coculture with T~ cells. 
Collectively, these studies suggest that  CD40 crosslinking 
may be necessary and sufficient for Ta cell-induced expres- 
sion of B7/BB1 and other accessory molecules on resting B 
cells. 
Prior studies also noted that  B cell expression of CD54 
may be enhanced by treatment  with  ot-CD40 mAbs  (49). 
Similar to what we observed in the current  study, these in- 
vestigators noted that normal B cells cocultured with soluble 
c~-CD40 mAbs may express approximately threefold greater 
levels of CD54 than  those of control or untreated  B cells. 
However, we find  that  ot-CD40 mAbs in  the  presence of 
CDw32-transfected L cells may affect a greater than 50-fold 
increase  in normal or leukemic B cell expression of CD54. 
This augmented effect likely is secondary to the crosslinking 
of CD40 that is achieved by the ot-CD40 mAb when deliv- 
ered on a membrane matrix of the CDw32-L cells. This cross- 
linking may more closely mimic the signal achieved through 
cognate T~-B cell interactions. 
Earlier studies demonstrated that crosslinking  surface Ig 
or class II MHC molecules induced resting B cells to express 
B7/BB1 (16-18). However, the greater than seven or fivefold 
increase in the expression of B7/BB1 that we observed upon 
crosslinking  CD40 either  with  o~-CD40 mAb or T~ cells, 
respectively, are greater than  three times the maximum in- 
crease in expression  of this surface antigen that we could affect 
by crosslinking slgM or HLA-DR. Our results demonstrate 
the existence of a novel, CD40-dependent mechanism for in- 
ducing B7/BB1 expression on B cells that appears more effec- 
tive than  these previously reported  stimuli. 
Other investigators who studied B cell proliferation  and 
Ig secretion induced by activated T  cells also identified sur- 
face  molecule(s)  that  may  be  involved  in  T~-B  cell  con- 
tact-dependent activation. Tohma and Lipsky (26) noted that 
mAbs that block CDlla/CD54 interactions could inhibit T~ 
cell-induced B cell proliferation, with the caveat that T~ cells 
unable to express CDlla retained the ability to stimulate B 
cells. In contrast,  we find that ot-CDlla mAb, even at high 
concentrations,  cannot inhibit T~ cell-induced B7/BB1 ex- 
pression. Our results are consistent, however, with more re- 
cent studies by Noelle et al.  (50),  who demonstrated  that 
blocking CD40 interaction with its coligand, a type II mem- 
brane glycoprotein recently identified on activated T cells (51), 
could inhibit T, cell-mediated B cell DNA,  RNA, and Ig 
synthesis.  These results support  the hypothesis that  the B 
cell stimulation induced by activated T  cells, whether mea- 
sured as proliferation,  Ig synthesis, or changes in surface pheno- 
type, is dependent primarily on a CD40-transduced signal(s). 
Previous work demonstrated that ot-CD40 mAb presented 
by CDw32-L cells could induce either normal or CLL-B cells 
to proliferate and secrete Ig in the presence of exogenous IL-4 
(42,  52,  53).  IL-4 is noted to increase  B cell expression of 
CD40 and to act as a costimulatory cytokine for anti-Ig-in- 
duced increases in [Ca  z+ ], (54).  Although this cytokine may 
enhance  the  effects  of  CD40  crosslinking,  we  find  that 
exogenous IL-4 is not necessary for e~-CD40-induced B cell 
expression of B7/BB1. Moreover, neutralizing  c~-IL-4 anti- 
body could not inhibit B cells from expressing increased levels 
of B7/BB1 or CD54 when cultured with either T~ cells, or 
CDw32-L cells and a-CD40 mAbs. Collectively,  these studies 
indicate that IL-4, although capable of augmenting the sig- 
nalling induced by CD40 crosslinking,  is neither necessary 
nor sufficient to affect  the phenotypic changes that we ob- 
served on B cells  exposed to  activated T  cells. 
In addition to the increased expression of B cell accessory 
molecules induced by CD40 signalling,  a crucial finding of 
the present work is that such T~ cell-induced changes have 
functional significance for B cell APC capacity. Previous studies 
indicated that  small resting  B cells are poor APCs for pri- 
mary responses, but may be effective after the responding T 
cell population has been activated (7,  55). We find that T~ 
cells (or cr  mAbs and CDw32-L cells) in fact may in- 
duce changes in CLL cells or normal resting B cells that make 
these cells  significantly better presenters  of alloantigen.  In 
this regard,  induced expression of B7/BB1 appears to be a 
crucial factor. CTLA4Ig, a hybrid recombinant molecule that 
can bind B7/BB1 and thereby block B7/BB1-CD28 interac- 
tions (41, 56), can affect >--75% inhibition  of the MLR be- 
tween stimulated CLL or normal B cells and allogeneic T 
cells. Increased expression of CD54, or its coligand CDlla, 
also may be important, as c~-CD11a mAbs inhibited the MLR 
>45%  when used alone, but >95%  when combined with 
CTLA4Ig. This conclusion is in agreement with other studies 
demonstrating  that expression of B7/BB1 or CD54 is im- 
portant  in effecting allogeneic T  cell proliferation  (18,  19, 
41, 49, 57). Collectively, these functional studies support the 
general hypothesis that activated T cells that express the CD40 
ligand may not only "help" B cells differentiate into Ig secreting 
cells, but also may induce B cells into becoming stimulatory 
APCs of other resting  T  ceils. 
In  this regard,  it is noteworthy that  CD40 also may be 
expressed on thymic epithelial cells (58) and dendritic cells 
(59), either of which may be involved in T cell development 
and/or activation. Already, CD40 crosslinking on thymic ep- 
ithelial cells has  been noted to induce production  of GM- 
CSF (58). Conceivably, these cells also may receive inductive 
signals  from CD40 ligand-expressing T cells that could en- 
hance  their  capacity to act as stimulatory  APCs. 
That  T  cells  activated by TCR crosslinking  acquire the 
capacity to induce B7/BB1 expression on resting B cells may 
have implications for the generation of normal immune re- 
sponses, the maintenance of self-tolerance,  and the initiation 
and/or progression of autoimmmune disease. Activated T cells 
may induce expression of B7/BB1 and other accessory mole- 
cules on resting B cells in an antigen-independent  manner. 
Such stimulated B cells may engage nonactivated T cells specific 
for an antigen(s) presented by such cells. This, in turn,  may 
induce CD40 ligand expression on these previously nonacti- 
vated antigen-specific T  cells, allowing for an amplification 
of both the T and B cell immune response. However, should 
autoantibody-produdng B cells interact  with activated T cells, 
then such cells may be able to stimulate T cells that are reac- 
tive to  B  cell-presented  self-antigens,  similar  to  B7/BB1- 
932  T, Cells Induce B7/BB1 Expression on Normal or Leukemic B Cells expressing APCs that encounter T cells specific for non-self 
antigens (18, 20, 21). Indeed, Lin et al., and Mamula et al. 
have noted that activation of autoreactive B ceils may break 
T  cell tolerance to self-antigens.  This mechanism also may 
contribute to the loss of self-tolerance that sometimes accom- 
panies persistent and/or repeated challenge with antigen, such 
as in adjuvant- or collagen-induced arthritis (62, 63). In this 
scenario, not only may autoantibodies be produced, but also, 
self-reactive  T  cells may become activated, thus potentially 
fueling a sustained autoimmune response. 
Eynon and Parker (10) noted that in vivo challenge with 
the soluble, monomeric antigen (F[ab] fragments of rabbit- 
or-mouse IgD)  resulted in  antigen-specific T  cell  anergy, 
whereas challenge with divalent F(ab')2 rabbit-o~-mouse IgD 
antigen resulted in a vigorous immune response to rabbit Ig. 
In the absence of slg crosslinking, they propose that B cells 
may present antigen in a fashion that induces antigen-specific 
T cell anergy. Whatever TCR crosslinking occurs on antigen- 
specific T cells as a consequence of their interaction with such 
APCs may not be suffident to induce these cells into becoming 
like Ta cells that are capable of stimulating expression of ac- 
cessory molecules on neighboring B cells. This is similar to 
what we noted with B cells cocultured with allogeneic Tr 
cells. Even though many Tr cells may undergo TCR cross- 
linking upon encounter with alloantigen, these Tr cells do 
not induce the B cells to express substantially higher levels 
of B7/BB1 or CD54. Either allostimulation is not sufficient 
to induce expression of CD40 ligand on such T cells, or other 
factors  may interfere with the signals  transduced by CD40 
crosslinking on bystander B cells. Further investigation of 
the kinetics of B7/BB1 and CD40 ligand-induced expres- 
sion are required to determine what role this bidirectional 
signalling  pathway  might  play  in  the  initiation  and/or 
amplification of normal or autoreactive immune responses. 
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